Full Press Release Details
Purple Biotech Reports Third Quarter 2022 Financial
Well capitalized with cash runway through 2024
Clinical progress for both programs, CM24 and
REHOVOT, Israel, November 8, 2022 -- (GLOBE
NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing
first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion
and drug resistance, today announced financial results for the third quarter ended September 30, 2022.
"As we prepare for 2023, we are advancing
the clinical development of our two lead investigational assets, CM24 and NT219, and exploring additional options to build the Company's
pipeline of first-in-class assets for treatment of cancers with high unmet clinical need," said Gil Efron, Chief Executive Officer
of Purple Biotech. "Purple is well positioned with a cash runway to meet clinical milestones through 2024. In addition to our financial
results, we are proud to provide our corporate update focused on enhancing our clinical program."
CM24 Study Design Update
The Company has amended the Phase 2 clinical trial
evaluating the use of its monoclonal antibody CM24, a new immune checkpoint inhibitor, in combination with the PD-1 inhibitor Opdivo
(nivolumab) plus chemotherapy for patients with 2L metastatic pancreatic cancer (PDAC). The clinical trial design has been amended to
randomize the study comparing CM24+nivolumab+standard-of-care (SoC) chemotherapy against SoC chemotherapy alone. The study is ongoing,
and patients are already being treated in a run-in portion of the study, which includes up to 18 patients followed by approximately 60
patients in the randomized part of the study. Interim analysis expected in the second half of 2023 and a topline report on the overall
study at the end of 2024.
NT219 Study Progress
In the monotherapy arm of the Phase 1/2 clinical
trial for NT219, participants are being treated at the 50mg/kg dose level, which is the last dose to be evaluated for monotherapy. In
the combination arm of NT219+cetuximab of the same study, participants are receiving a 24 mg/kg dose of NT219, the penultimate dose being
evaluated in this arm. As this trial progresses, we expect to report the recommended Phase 2 dose (RP2D) for monotherapy in the first
quarter of 2023, and RP2D for the combination with cetuximab in the second quarter of 2023.
The Purple Biotech team welcomed Lior Fhima, CPA,
MBA, as Chief Financial Officer of the Company in November. Mr. Fhima brings deep expertise in financial management in the pharmaceutical
industry and strong managerial capabilities. We look forward to his contributions in growing Purple Biotech as we advance our first-in-class
"We anticipate that 2023 will be an important
year for Purple Biotech, as we plan to report data from our ongoing clinical programs for our two investigational oncology assets. Additionally,
we will continue to pursue potential collaborations and commercial opportunities for CM24 and NT219, as well as acquisitions or collaborations
related to other first-in-class oncology therapeutics that may be able to address large unmet clinical needs for patients living with
devastating cancers," added Mr. Efron.
Financial Results for the three Months Ended
Research and Development Expenses were
$3.5 million, an increase of $1.9 million, or 118.8%, compared to $1.6 million in the same period of 2021. The increase was mainly due
to an increase of $0.5 million in CMC expenses in support of our clinical studies, an increase of $0.8 million for our clinical trials
expenses and $0.3 million in payroll and share based payment expenses in support our growing development activities.
Selling, General and Administrative Expenses
were $1.6 million, an increase of $0.2 million, or 14.3%, compared to $1.4 million in the same period of 2021. The increase was mainly
due to increase of $0.2 million in payroll expenses.
Operating Loss was $5.1 million, an increase
of $2.1 million, or 66.67%, compared to $3.0 million in the same period of 2021. The increase was mainly due to the increase in research
and development expenses.
On a non-IFRS basis (as reconciled below), adjusted
operating loss was $4.4 million, an increase of $1.7 million, compared to $2.7 million in the same period of 2021.
Net Loss for the three months ended
September 30, 2022 was $4.8 million, or $0.27 per basic and diluted ADS, compared to a net loss of $3.1 million, or $0.17 per basic and
diluted ADS, in the three months ended September 30, 2021. Adjusted net loss for the three months ended September 30, 2022 was
$4.1 million, an increase from $2.6 million in the three months ended September 30, 2021.
Financial Results for the Nine Months Ended
Research and Development Expenses were
$11.5 million, an increase of $2.9 million, or 33.7%, compared to $8.6 million in the same period of 2021. The increase was mainly due
to an increase of $1.06 million in CMC expenses in support of our clinical studies, an increase of $0.9 million for our clinical trials
expenses and $0.7 million in payroll and share based payment expenses in support our growing development activities.
Sales, General and Administrative Expenses
were $4.5 million, compared to $4.6 million in the same period of 2021, a decrease of $0.1 million.
Operating Loss from continuing operations
was $16 million, an increase of $2.8 million, or 21.2%, compared to $13.2 million in the same period of 2021. The increase was mainly
due to the increase in research and development expenses.
On a non-IFRS basis (as reconciled below), adjusted
operating loss was $14.4 million, an increase of $3.0 million, compared to $11.4 million in the same period of 2021, mainly due
to an increase in R&D expenses.
Net Loss for the first nine months
ended September 30, 2022 was $15.7 million, or $0.87 per basic and diluted ADS, compared to a net loss of $13 million, or $0.75 per basic
and diluted ADS, in the same period of 2021. The increase in net loss was mainly due to an increase of $2.8 million in operating expenses.
Adjusted net loss for nine months ended September 30, 2022 was $14.1 million, an increase from $11.3 million in the nine months
ended September 30, 2021.
As of September 30, 2022, the Company had a total
amount of $35.7 million in cash, cash equivalent and short and long term deposits.
During the nine months ended September 30, 2022,
the Company sold, under the Open Market Sale Agreementsm with Jefferies LLC, approximately 453 thousand ADSs, at an average
price of $2.92 per ADS. Net proceeds to the Company, were approximately $1.3 million, net of issuance expenses.
About Purple Biotech
Purple Biotech Ltd. is
a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance. The Company's
oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3.
In a Phase 1/2 study of NT219, the Company is currently advancing NT219 as a monotherapy treatment of solid tumors, and in a dose escalation
of NT219 in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck cancer
(SCCHN) or colorectal adenocarcinoma. These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in
combination with cetuximab in patients with recurrent and metastatic SCCHN. CM24 is a humanized monoclonal antibody that blocks CEACAM1,
an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24
as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma
(PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 1/2 clinical trials to
evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo ) in addition to chemotherapy. The Company's corporate
headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that
are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that
are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target", "will",
"project", "forecast", "continue" or "anticipate" or their negatives or variations of these words
or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current
views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and
unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance
or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans,